---
title: "Prime Medicine | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 856 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285549620.md"
datetime: "2026-05-07T12:18:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285549620.md)
  - [en](https://longbridge.com/en/news/285549620.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285549620.md)
---

# Prime Medicine | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 856 K

Revenue: As of FY2026 Q1, the actual value is USD 856 K, missing the estimate of USD 884.22 K.

EPS: As of FY2026 Q1, the actual value is USD -0.28.

EBIT: As of FY2026 Q1, the actual value is USD -51.68 M.

The provided text indicates that the detailed financial and operational metrics, as well as any outlook or guidance, are not contained within the provided text of the Form 8-K itself for Prime Medicine, Inc.

### Related Stocks

- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)

## Related News & Research

- [Lifesci Capital Begins Coverage on Prime Medicine (NYSE:PRME)](https://longbridge.com/en/news/270638375.md)
- [JonesTrading Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)](https://longbridge.com/en/news/285766225.md)
- [FS KKR Capital to post investor presentations on website after market close](https://longbridge.com/en/news/286815114.md)
- [Capital City Bank Group posts Q1 2026 investor presentation on website](https://longbridge.com/en/news/286599786.md)
- [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md)